D M Witt

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program
    Daniel M Witt
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado Region, Westminster, USA
    Pharmacotherapy 23:360-8. 2003
  2. ncbi Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes
    Jung Chuang
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente of Colorado, 11245 Huron St, Westminster, CO 80234, USA
    Chest 126:1262-6. 2004
  3. ncbi Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy
    Daniel M Witt
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente of Colorado, Westminster, USA
    Chest 127:1515-22. 2005
  4. ncbi Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation
    Thomas Delate
    Kaiser Permanente Colorado, 16601 E Centretech Pkwy, Aurora, CO 80011, USA
    Chest 131:816-22. 2007
  5. ncbi Initiation and reinitiation of anticoagulation therapy
    Daniel M Witt
    Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Semin Hematol 48:295-301. 2011
  6. ncbi The Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service as a model of modern anticoagulant care
    Daniel M Witt
    Clinical Pharmacy Services, Kaiser Permanente Colorado, 16601 East Centretech Parkway, Aurora, CO 80011, USA
    Thromb Res 123:S36-41. 2008
  7. ncbi Outcomes and predictors of very stable INR control during chronic anticoagulation therapy
    Daniel M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, USA
    Blood 114:952-6. 2009
  8. ncbi Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy
    D M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, CO, USA
    J Thromb Haemost 7:1982-9. 2009
  9. ncbi Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users
    D M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, CO, USA
    J Thromb Haemost 8:744-9. 2010
  10. ncbi Optimizing use of current anticoagulants
    Daniel M Witt
    Clinical Pharmacy Services and Research, Department of Pharmacy, Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Hematol Oncol Clin North Am 24:717-26, viii. 2010

Detail Information

Publications27

  1. ncbi Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program
    Daniel M Witt
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado Region, Westminster, USA
    Pharmacotherapy 23:360-8. 2003
    ..Although subsequent research with AB-rated (i.e., bioequivalent) warfarin did not confirm initial concerns, the issue is not settled for all clinicians...
  2. ncbi Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes
    Jung Chuang
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente of Colorado, 11245 Huron St, Westminster, CO 80234, USA
    Chest 126:1262-6. 2004
    ..Anecdotal observations by pharmacists monitoring anticoagulated patients indicate that blood samples collected in 2.7-mL (pediatric) evacuated tubes frequently produced falsely elevated international normalized ratio (INR) results...
  3. ncbi Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy
    Daniel M Witt
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente of Colorado, Westminster, USA
    Chest 127:1515-22. 2005
    ..A growing body of reports has documented the ability of anticoagulation management services to help patients receiving warfarin therapy achieve better outcomes compared to the care provided by their personal physicians (ie, usual care)...
  4. ncbi Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation
    Thomas Delate
    Kaiser Permanente Colorado, 16601 E Centretech Pkwy, Aurora, CO 80011, USA
    Chest 131:816-22. 2007
    ..This study describes the rate of falsely elevated INRs and characteristics predictive of falsely elevated INRs...
  5. ncbi Initiation and reinitiation of anticoagulation therapy
    Daniel M Witt
    Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Semin Hematol 48:295-301. 2011
    ..All anticoagulants increase the risk of bleeding and should therefore only be initiated in appropriately selected patients with sufficiently low underlying bleeding risk...
  6. ncbi The Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service as a model of modern anticoagulant care
    Daniel M Witt
    Clinical Pharmacy Services, Kaiser Permanente Colorado, 16601 East Centretech Parkway, Aurora, CO 80011, USA
    Thromb Res 123:S36-41. 2008
    ..Results of various CPAS research projects have been published in the peer-reviewed medical literature...
  7. ncbi Outcomes and predictors of very stable INR control during chronic anticoagulation therapy
    Daniel M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, USA
    Blood 114:952-6. 2009
    ..0 or higher or chronic diseases. We hypothesize that many patients demonstrating stable INR control could be safely treated with INR recall intervals greater than the traditional 4 weeks...
  8. ncbi Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy
    D M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, CO, USA
    J Thromb Haemost 7:1982-9. 2009
    ..To assess the effect of warfarin anticoagulation therapy (AC) on the incidence of colon bleeding after elective colonoscopy with polypectomy and to identify independent predictors of post-polypectomy colon bleeding...
  9. ncbi Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users
    D M Witt
    Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service, Lafayette, CO, USA
    J Thromb Haemost 8:744-9. 2010
    ..For patients whose INR values are nearly always therapeutic, less frequent INR monitoring may be feasible...
  10. ncbi Optimizing use of current anticoagulants
    Daniel M Witt
    Clinical Pharmacy Services and Research, Department of Pharmacy, Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Hematol Oncol Clin North Am 24:717-26, viii. 2010
    ..For patients able to achieve stable anticoagulation control, warfarin remains an important therapeutic option, delivering similar clinical outcomes at a fraction of the cost to the health care system...
  11. ncbi A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care
    Daniel M Witt
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado Region, Westminster, CO 80234, USA
    J Thromb Thrombolysis 15:113-8. 2003
    ..We sought to compare the outcomes of excessive anticoagulation episodes managed by CPAS pharmacists to traditional physician management...
  12. ncbi Quality measures and benchmarking for warfarin therapy
    Daniel M Witt
    Clinical Pharmacy Research and Applied Pharmacogenomics, Kaiser Permanente Colorado, 16601 East Centretech Parkway, Aurora, CO 80011, USA
    J Thromb Thrombolysis 31:242-8. 2011
    ....
  13. ncbi Clinical pharmacy anticoagulation services in a group model health maintenance organization
    D M Witt
    Kaiser Permanente, Rocky Mountain Division, Westminster, CO 80234, USA
    Pharm Pract Manag Q 18:34-55. 1998
    ..A program for treating patients with deep vein thrombosis in the outpatient setting using enoxaparin is also described...
  14. ncbi An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy
    Samuel G Johnson
    Clinical Pharmacy Services, Kaiser Permanente of Colorado, Aurora, CO 80011, USA
    J Thromb Thrombolysis 19:209-12. 2005
    ..However, anticoagulation therapy providers should manage these patients with the same diligence and care as patients without diabetes...
  15. ncbi Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization
    D J Tillman
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado Region, Denver, USA
    Arch Intern Med 160:2926-32. 2000
    ..Whether favorable results reported in controlled clinical trials are achievable in clinical practice is an important consideration...
  16. ncbi A descriptive evaluation of unfractionated heparin use during pregnancy
    Nathan P Clark
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, Lafayette, CO 80026, USA
    J Thromb Thrombolysis 27:267-73. 2009
    ..Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) do not cross the placenta and have demonstrated utility in the prevention and treatment of thrombosis during pregnancy...
  17. ncbi Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial
    Mary Beth Dowd
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente, Aurora, CO, USA
    J Thromb Thrombolysis 31:472-7. 2011
    ....
  18. ncbi Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy
    Marsha A Raebel
    Clinical Research Unit, Kaiser Permanente of Colorado, and the School of Pharmacy, University of Colorado, Denver, Colorado 80237 8066, USA
    Pharmacotherapy 25:1055-61. 2005
    ..To determine the frequency of monitoring of international normalized ratio (INR) within 14 days of coprescription of warfarin and antimicrobial therapy and to evaluate differences in INR monitoring among antimicrobials...
  19. ncbi Unfractionated heparin dose requirements targeting intermediate intensity antifactor Xa concentration during pregnancy
    Nathan P Clark
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, Lafayette, Colorado, USA
    Pharmacotherapy 30:369-74. 2010
    ..To describe unfractionated heparin (UFH) dosing requirements and monitoring parameters to achieve target antifactor Xa concentrations in pregnant women receiving intermediate-dose UFH therapy...
  20. ncbi A descriptive evaluation of routine complete blood count monitoring in patients receiving anticoagulation therapy
    Kandace V Anich
    Primary Care Clinical Pharmacy Services, Kaiser Permanente of Colorado, Westminster, CO, USA
    J Thromb Thrombolysis 20:183-8. 2005
    ..For most anticoagulated patients, routine CBC monitoring appears to be clinically unnecessary...
  21. ncbi Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy
    Nathan P Clark
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, 280 Exempla Circle, Lafayette, Colorado, USA
    Thromb Res 125:402-5. 2010
    ..3-0.7 u/ml during pregnancy. The objective of this study was to describe UFH doses and monitoring strategies required to achieve and maintain therapeutic anti-Xa intensity in a cohort of women treated with UFH during pregnancy...
  22. ncbi Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention
    Kari L Olson
    Pharmacy Department, Kaiser Permanente Colorado, 16601 E Centretech Parkway, Aurora, CO 80011, USA
    J Thromb Thrombolysis 29:316-21. 2010
    ..0; 95% CI 1.1-3.8). Post-stent treatment with warfarin, ASA, and clopidogrel was associated with a substantially greater likelihood of major hemorrhage than treatment with ASA and clopidogrel alone...
  23. ncbi Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service
    Samuel G Johnson
    Kaiser Permanente of Colorado, 16601 E Centretech Pkwy, Aurora, CO 80011, USA
    Chest 131:1500-7. 2007
    ....
  24. ncbi Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study
    Nathan P Clark
    Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, 280 Exempla Circle, Lafayette, CO 80026, USA
    Pharmacotherapy 28:960-7. 2008
    ..To quantify the absolute risk of thromboembolism associated with a significant subtherapeutic international normalized ratio (INR) in patients with previously stable anticoagulation while receiving warfarin...
  25. ncbi Outcomes associated with combined antiplatelet and anticoagulant therapy
    Samuel G Johnson
    Kaiser Permanente Colorado Region, Clinical Pharmacy Services, Aurora, CO 80011, USA
    Chest 133:948-54. 2008
    ..The objective of this study was to estimate and compare the incidence of adverse and coronary event rates between patients receiving warfarin monotherapy or warfarin and antiplatelet combination therapy...
  26. ncbi A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services
    Robin R Hill
    Department of Pharmacy, Kaiser Permanente, Aurora, CO 80014, USA
    J Thromb Thrombolysis 27:334-9. 2009
    ..To describe and compare warfarin therapy use and outcomes between warfarin-receiving patients in hospice or palliative care (HPC) and not in HPC...
  27. ncbi Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum
    David A Garcia
    University of New Mexico School of Medicine, Albuquerque, NM, USA
    Ann Pharmacother 42:979-88. 2008
    ....